Current Landscape of Antiviral Drug Discovery

F1000Res. 2016 Feb 22;5:F1000 Faculty Rev-202. doi: 10.12688/f1000research.7665.1. eCollection 2016.


Continued discovery and development of new antiviral medications are paramount for global human health, particularly as new pathogens emerge and old ones evolve to evade current therapeutic agents. Great success has been achieved in developing effective therapies to suppress human immunodeficiency virus (HIV) and hepatitis B virus (HBV); however, the therapies are not curative and therefore current efforts in HIV and HBV drug discovery are directed toward longer-acting therapies and/or developing new mechanisms of action that could potentially lead to cure, or eradication, of the virus. Recently, exciting early clinical data have been reported for novel antivirals targeting respiratory syncytial virus (RSV) and influenza (flu). Preclinical data suggest that these new approaches may be effective in treating high-risk patients afflicted with serious RSV or flu infections. In this review, we highlight new directions in antiviral approaches for HIV, HBV, and acute respiratory virus infections.

Keywords: Drug discovery; F-protein; hepatitis B virus; heteroaryldihydropyrimidines; human immunodeficiency virus; influenza; monoclonal antibody; phenylpropenamides; respiratory syncytial virus.

Publication types

  • Review

Grant support

The author(s) declared that no grants were involved in supporting this work.